EptifibatideThird Party Manufacturing in India

Eptifibatide works by preventing blood cells called platelets from clumping together, thereby reducing the risk of dangerous blood clots in the blood vessels supplying the heart.

As a cyclic heptapeptide antiplatelet agent, Eptifibatide binds reversibly to the glycoprotein IIb/IIIa receptor on the surface of human platelets. This receptor is the final common pathway for platelet aggregation. By blocking the receptor, Eptifibatide prevents the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. Because these molecules cannot bind, platelets are unable to form bridges between one another, halting the cascade of thrombus formation.

Unlike aspirin or clopidogrel, which work upstream in platelet activation pathways, Eptifibatide targets the final step of aggregation directly. This makes it an extremely potent and fast-acting intervention during acute cardiac events or invasive procedures, with platelet function returning to normal within hours after the infusion is stopped.

Eptifibatide (CAS 188627-80-7) is a widely prescribed cyclic heptapeptide antiplatelet agent that plays a key role in acute cardiac care. Celesta provides high-quality services for Eptifibatide third party manufacturing in India, delivering sterile injectables to domestic and export markets.

Therapeutic Uses

Eptifibatide is prescribed for the treatment of:

• Acute Coronary Syndrome (ACS): Administered to manage patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) who are managed medically or undergoing invasive treatment.
• Percutaneous Coronary Intervention (PCI): Utilized to prevent thrombotic complications during balloon angioplasty, atherectomy, and intracoronary stenting.
• Myocardial Infarction Prevention: Used to reduce the rate of death and recurrent ischemic events in high-risk cardiac patients.

Choosing an Eptifibatide Manufacturer in India

Eptifibatide is a highly specialized critical-care medicine used in cardiac emergency setups and catheterization labs. Its demand is driven by the rising global prevalence of cardiovascular diseases and the increasing number of interventional cardiac procedures. Sourcing from a WHO-GMP certified manufacturer in India guarantees high-purity formulations that prevent degradation and maintain stability. Sourcing through a WHO-GMP certified partner ensures high-quality sterile products that meet IP and USP monographs, which is essential for hospital tender systems and international export markets.

To place an order or discuss customization, please contact our team. You can view our cardiovascular portfolio on our manufacturing listing page or read about our capabilities on our contract manufacturing page.

This makes Eptifibatide one of the most sought-after critical-care cardiac molecules for third party manufacturing in India, with consistent demand from hospital distributors and export markets.